| Phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitors for the treatment of inflammation and autoimmune disease. | |
| | |
MedLine Citation:
|
PMID: 20017720 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Phosphoinositide 3-kinase gamma (PI3Kgamma) is a lipid kinase in leukocytes that generates phosphatidylinositol 3,4,5-trisphosphate to recruit and activate downstream signaling molecules. Distinct from other members in the PI3K family, PI3Kgamma is activated by G-protein coupled-receptors responding to chemotactic ligands. PI3Kgamma plays an important role in migration of both myeloid and lymphoid cells. It is also required for other leukocyte functions such as neutrophil oxidative burst, T cell proliferation and mast degranulation. Mice with PI3Kgamma inactivated by genetic or pharmacological approaches are protected from disease development in a number of inflammation and autoimmune disease models. The function of PI3Kgamma depends on its kinase activity and therefore it has been suggested by many reports that small molecules inhibiting its kinase activity could be promising for the treatment of inflammation and autoimmune diseases. Over the last five years, a number of pharmaceutical companies have reported a wide variety of PI3Kgamma inhibitors, of which several x-ray crystal structures with PI3Kgamma have been elucidated. The structural characteristics and selectivity profiles of these inhibitors, in particular thiazolidinones and 2-aminoheterocycles, and those disclosed in related patent applications are summarized in this review. |
| | |
Authors:
|
Jennifer D Venable; Michael K Ameriks; Jonathan M Blevitt; Robin L Thurmond; Wai-Ping Fung-Leung |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Recent patents on inflammation & allergy drug discovery Volume: 4 ISSN: 1872-213X ISO Abbreviation: Recent Pat Inflamm Allergy Drug Discov Publication Date: 2010 Jan |
Date Detail:
|
Created Date: 2009-12-18 Completed Date: 2010-06-07 Revised Date: 2011-06-17 |
Medline Journal Info:
|
Nlm Unique ID: 101309297 Medline TA: Recent Pat Inflamm Allergy Drug Discov Country: United Arab Emirates |
Other Details:
|
Languages: eng Pagination: 1-15 Citation Subset: IM |
Affiliation:
|
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA92121, USA. wleung@its.jnj.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Autoimmune Diseases / drug therapy* Class Ib Phosphatidylinositol 3-Kinase Enzyme Inhibitors / pharmacology*, therapeutic use Humans Inflammation Isoenzymes / antagonists & inhibitors Patents as Topic Phosphatidylinositol 3-Kinases / antagonists & inhibitors* Signal Transduction Structure-Activity Relationship Substrate Specificity Thiazolidinediones / chemistry, pharmacology* |
| Chemical | |
Reg. No./Substance:
|
0/Enzyme Inhibitors; 0/Isoenzymes; 0/Thiazolidinediones; EC 2.7.1.-/Phosphatidylinositol 3-Kinases; EC 2.7.1.137/Class Ib Phosphatidylinositol 3-Kinase; EC 2.7.1.137/PIK3CG protein, human; EC 2.7.1.153/Pik3cg protein, mouse |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cliff swallows, swallow bugs, and West Nile virus: an unlikely transmission mechanism.
Next Document: Telomere Maintenance as Therapeutic Target in Embryonal Tumours.